



DAFTAR PUSTAKA

- Al-Agha, O.M., Huwait, H.F., Chow, C., Yang, W., Senz, J., Kalloger, S.E., Huntsman, D.G., Young, R.H., Gilks, C.B., 2011. FOXL2 is a sensitive and specific marker for sex cord-stromal tumors of the ovary. *Am. J. Surg. Pathol.* 35, 484–494.
<https://doi.org/10.1097/PAS.0b013e31820a406c>
- Andreu-Vieyra C, Chen R & Matzuk MM 2008 Conditional deletion of the retinoblastoma (Rb) gene in ovarian granulosa cells leads to premature ovarian failure. *Molecular Endocrinology* 22 2141–2161. (doi:10.1210/me.2008-0033)
- Benayoun BA, Batista F, Auer J, Dipietromaria A, L’Ho[^]te D, De Baere E & Veitia RA 2009 Positive and negative feedback regulates the transcription factor FOXL2 in response to cell stress: evidence for a regulatory imbalance induced by disease-causing mutations. *Human Molecular Genetics* 18 632–644. (doi:10.1093/hmg/ddn389)
- Benayoun BA, Caburet S, Dipietromaria A, Georges A, D’Haene B, Pandaranayaka PJE, L’Ho[^]te D, Todeschini A-L, Krishnaswamy S, Fellous M et al. 2010 Functional exploration of the adult ovarian granulosa cell tumor-associated somatic FOXL2 mutation p.Cys134Trp (c.402COG). *PLoS ONE* 5 e8789. (doi:10.1371/journal.pone.0008789)
- Berek, J.S., Kehoe, S.T., Kumar, L., Friedlander, M., 2018. Cancer of the ovary, fallopian tube, and peritoneum. *Int. J. Gynecol. Obstet.* 143, 59–78.
<https://doi.org/10.1002/ijgo.12614>
- Buza, N., Wong, S., Hui, P., 2017. FOXL2 Mutation Analysis of Ovarian Sex Cord-Stromal Tumors. *Int. J. Gynecol. Pathol.* 37, 305–315.
<https://doi.org/10.1097/pgp.0000000000000426>



Caburet S, Georges A, L'Ho[^]te D, Todeschini A-L, Benayoun BA & Veitia RA 2012 The transcription factor FOXL2: at the crossroads of ovarian physiology and pathology.

Molecular and Cellular Endocrinology 356 55–64. (doi:10.1016/j.mce.2011.06.019)

Cheng J, Chang H, Qiu X, Fang L, Leung PCK. Biochemical and Biophysical Research

Communications FOXL2-induced follistatin attenuates activin A-stimulated cell proliferation in human granulosa cell tumors. Biochem Biophys Res Commun [Internet].

Elsevier Inc.; 2014;443(2):537–42

Colombo N, Peiretti M, Garbi A, Carinelli S, Marini C, Sessa C. clinical practice guidelines

Non-epithelial ovarian cancer : ESMO Clinical Practice Guidelines for diagnosis , treatment. 2012;23(Supplement 7)

Crispens MA. Ovarian Cancer. 2nd ed. NCNN Clinical Practice Guidelines in Oncology; 2015

Cunningham, Leveno, Bloom, Spong, Dashe, Hoffman, et al. williams obstetrics. 24th ed.

Texas: McGraw-Hill Education; 2014

D'Angelo, E., Mozos, A., Nakayama, D., Espinosa, Í., Catusus, L., Muñoz, J., Prat, J., 2011.

Prognostic significance of FOXL2 mutation and mRNA expression in adult and juvenile granulosa cell tumors of the ovary. Mod. Pathol. 24, 1360–1367.

<https://doi.org/10.1038/modpathol.2011.95>

Disaia P, Creasman W. Clinical Gynecologic Oncology. 7th ed. Philadelphia: Mosby Elsevier;

2007

Escudero JM, Haller JL, Clay CM & Escudero KW 2010 Microarray analysis of Foxl2

mediated gene regulation in the mouse ovary derived KK1 granulosa cell line: over-expression of Foxl2 leads to activation of the gonadotropin releasing hormone receptor

gene promoter. Journal of Ovarian Research 3 4. (doi:10.1186/1757-2215-3-4)



- Gatta, G., Van Der Zwan, J.M., Casali, P.G., Siesling, S., Dei Tos, A.P., Kunkler, I., Otter, R., Licitra, L., Mallone, S., Tavilla, A., et al., 2011. Rare cancers are not so rare: The rare cancer burden in Europe. *Eur. J. Cancer* 47, 2493–2511. <https://doi.org/10.1016/j.ejca.2011.08.008>
- Goulvent, T., Ray-Coquard, I., Borel, S., Haddad, V., Devouassoux-Shisheboran, M., Vacher-Lavenu, M.C., Pujade-Laurraine, E., Savina, A., Maillet, D., Gillet, G., Treilleux, I., Rimokh, R., 2016. DICER1 and FOXL2 mutations in ovarian sex cord-stromal tumours: A GINECO Group study. *Histopathology* 68, 279–285. <https://doi.org/10.1111/his.12747>
- Hoffman, Schorge, Schaffer, Halvorson, Bradshaw, Cunningham. *Williams Gynecology*. 2nd ed. Texas: McGraw-Hill Education; 2012
- Holschneider CH, Berek JS. Ovarian Cancer : Epidemiology , Biology , and prognostic factors. *Semin surg oncol* 2000; Jul – Aug 3–10.
- Isonishi S, Ogura A, Kiyokawa T, Suzuki M, Kunito S, Hirama M, et al. Alpha-fetoprotein (AFP)-producing ovarian tumor in an elderly woman. 2009;125:70–3
- Jamieson S, Fuller PJ. Molecular Pathogenesis of Granulosa Cell Tumors of the Ovary. 2014;33(February 2012):109–44 (doi:10.1210/er.2011-0014)
- Kelly PJ, Archbold P, Price JH, Cardwell C, Mccluggage WG. Serum CA19 . 9 levels are commonly elevated in primary ovarian mucinous tumours but cannot be used to predict the histological subtype. 2015;169–74
- Kim, M.S., Hur, S.Y., Yoo, N.J., Lee, S.H., 2010. Mutational analysis of FOXL2 codon 134 in granulosa cell tumour of ovary and other human cancers. *J. Pathol.* 221, 147–152. <https://doi.org/10.1002/path.2688>



Kyung MS. Serum CA19-9 as a Predictor of Malignancy in Primary Ovarian Mucinous

Tumors : A Matched Case-Control Study. 2014;1334–9

Lenhard M, Tsvilina A, Schumacher L, Kupka M, Ditsch N, Mayr D, et al. Human chorionic gonadotropin and its relation to grade , stage and patient survival in ovarian cancer Translational oncology. 2012

Manuylov NL, Smagulova FO, Leach L & Tevosian SG 2008 Ovarian development in mice requires the GATA4–FOG2 transcription complex. Development 135 3731–3743. (doi:10.1242/dev.024653)

McConechy, M.K., Farkkila, A., Horlings, H.M., Talhouk, A., Unkila-Kallio, L., Van Meurs, H.S., Winnie, Y., Rozenberg, N., Andersson, N., Zaby, K., Bryk, S., Butzow, R., Halfwerk, J.B.G., Hooijer, G.K.J., Van De Vijver, M.J., Buist, M.R., Kenter, G.G., Brucker, S.Y., Kramer, B., Staebler, A., Bleeker, M.C.G., Heikinheimo, M., Kommoss, S., Gilks, C.B., Anttonen, M., Huntsman, D.G., 2016. Molecularly defined adult granulosa cell tumor of the ovary: The clinical phenotype. J. Natl. Cancer Inst. 108, 1–5. <https://doi.org/10.1093/jnci/djw134>

Mctavish KJ, Nonis D, Hoang YD, Shimasaki S. Molecular and Cellular Endocrinology Granulosa cell tumor mutant FOXL2 C134W suppresses GDF-9 and activin A-induced follistatin transcription in primary granulosa cells. Mol Cell Endocrinol [Internet]. Elsevier Ireland Ltd; 2013;372(1-2):57–64

Morin RD, Sc M, Clarke BA, Ch B, Wiegand KC, Sc B, et al. Mutation of FOXL2 in Granulosa Cell Tumors of the Ovary. 2009

Moumne´ L, Dipietromaria A, Batista F, Kocer A, Fellous M, Pailhoux E & Veitia RA 2008 Differential aggregation and functional impairment induced by polyalanine expansions in



FOXL2, a transcription factor involved in cranio-facial and ovarian development. Human

Molecular Genetics 17 1010–1019. (doi:10.1093/hmg/ddm373)

Nunes N, Foo X, Naftalin J, Jurkovic D. Use of IOTA simple rules for diagnosis of ovarian cancer : 2014;(October):503–14

Osama M., Al-Agha., Hassan, F., Christine, C., Winnie, Y., David, G., Robert, H., Blake, G., 2011. FOXL2 is a sensitive and specific Marker for Sex Cord-Stromal Tumors of theOvary. Am J Surg Pathol. 35, 484-494

PannetierM, Fabre S, Batista F,Kocer A,Renault L, Jolivet G,Mandon-PepinB, Cotinot C, Veitia R & Pailhoux E 2006 FOXL2 activates P450 aromatase gene transcription: towards a better characterization of the early steps of mammalian ovarian development. Journal of Molecular Endocrinology 36 399–413.

Pisarska MD, Bae J, Klein C & Hsueh AJW 2004 Forkhead 12 is expressed in the ovary and represses the promoter activity of the steroidogenic acute regulatory gene. Endocrinology 145 3424–3433.

Pode D, Kopo S, Gimmon Z. Serum Lactic Dehydrogenase : A Tumor Marker of Ovarian Dysgerminoma in a Female Pseudohermaphrodite. 1984;113:110–3

Ray-Coquard, I., Morice, P., Lorusso, D., Prat, J., Oaknin, A., Pautier, P., Colombo, N., 2018. Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann. Oncol. 29, iv1-iv18. <https://doi.org/10.1093/annonc/mdy001>

Rosario, R., Cohen, P.A., Shelling, A.N., 2014. The role of FOXL2 in the pathogenesis of adult ovarian granulosa cell tumours. Gynecol. Oncol. 133, 382–387. <https://doi.org/10.1016/j.ygyno.2013.12.012>



Rosario R, Wilson M, Cheng W, Payne K, Cohen PA, Fong P, et al. *Gynecologic Oncology*

Adult granulosa cell tumours (GCT): Clinicopathological outcomes including FOXL2 mutational status and expression. *Gynecol Oncol* [Internet]. Elsevier Inc.; 2013;131(2):325–9

Rusner, C., Trabert, B., Katalinic, A., Kischke, J., Emrich, K., Stang, A., 2013. Incidence patterns and trends of malignant gonadal and extragonadal germ cell tumors in Germany, 1998-2008. *Cancer Epidemiol.* 37, 370–373. <https://doi.org/10.1016/j.canep.2013.04.003>

Shah, S.P., Kobel, M., Senz, J., Morin, R.D., Clarke, B.A., Clarke, M.B., Wiegand, K.C., Leung, G., Zayed, A., Mehl, E., Kalloger, S.E., 2009. Mutation of FOXL2 in Granulosa-Cell Tumors of the Ovary. *N. Engl. J. Med.* 360, 2719–29. <https://doi.org/10.1056/NEJMoa0902542>

Stang, A., Trabert, B., Wentzensen, N., Cook, M.B., Rusner, C., Oosterhuis, J.W., McGlynn, K.A., 2012. Gonadal and extragonadal germ cell tumours in the United States, 1973-2007. *Int. J. Androl.* 35, 616–625. <https://doi.org/10.1111/j.1365-2605.2011.01245.x>